Notice of a Public Consultation Meeting on Proposed Revisions to the NIH Guidelines for Research Involving Recombinant DNA Molecule (NIH Guidelines), 17202 [E9-8478]

Download as PDF 17202 Federal Register / Vol. 74, No. 70 / Tuesday, April 14, 2009 / Notices Dated: April 7, 2009. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–8479 Filed 4–13–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: April 7, 2009. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–8481 Filed 4–13–09; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Aneurysm Trial. Date: April 23, 2009. Time: 3:15 p.m. to 5:15 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Richard D. Crosland, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529, 301– 594–0635, rc218u@nih.gov. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Review of NINDS PPG on CA∧2+ Signaling in Spines. Date: April 24, 2009. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Ernest W Lyons, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/DHHS Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892– 9529, 301–496–4056, lyonse@ninds.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research VerDate Nov<24>2008 17:36 Apr 13, 2009 Jkt 217001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of a Public Consultation Meeting on Proposed Revisions to the NIH Guidelines for Research Involving Recombinant DNA Molecule (NIH Guidelines) There will be a public consultation meeting to solicit stakeholder input regarding the proposed revisions to the NIH Guidelines. The meeting will be held on Tuesday, June 23, 2009 at the Hyatt Regency Crystal City, 2799 Jefferson Davis Highway, Arlington, Virginia, 22202, from approximately 8 a.m. to 5 p.m. Discussions will focus on the proposed revisions to the NIH Guidelines which include: (1) Broadening the scope of the NIH Guidelines, which currently cover laboratory and clinical research involving DNA molecules created via recombinant techniques (i.e., joining of DNA molecules), to apply to nucleic acids that are synthesized chemically or by other means without the use of recombinant technology; (2) Revising the criteria for determining when the introduction of a drug resistance trait into a microorganism must be reviewed by the Recombinant DNA Advisory Committee and approved by the NIH Director; and (3) Changing the level of review required for recombinant or synthetic experiments involving more than one-half but less than two-thirds of the genome of certain viruses in tissue culture as described in Section III–E–1 of the NIH Guidelines. The Notice of Consideration of a Proposed Action under the NIH Guidelines was published in the Federal Register on March 4, 2009 (74 FR 9411) and may be located at the following link: https://oba.od.nih.gov/ rdna/rdna.html. For further information concerning this meeting contact Ms. Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, Office of the Director, National Institutes of Health, 6705 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 Rockledge Drive, Room 750, Bethesda, MD 20892–7985, 301–496–9838, lewallenl@od.nih.gov. The meeting will be open to the public, with attendance limited to the space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed above in advance of the meeting. A draft agenda and additional information for the meeting will be posted on the OBA Web site: https:// oba.od.nih.gov/rdna/rdna.html. Background and supplemental information may also be obtained by contacting NIH OBA by e-mail oba@od.nih.gov. Dated: April 8, 2009. Jacqueline Corrigan-Curay, Acting Director, Office of Biotechnology Activities, National Institutes of Health. [FR Doc. E9–8478 Filed 4–13–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Request for Research Sites To Measure Composition of Sealed Area Atmosphere in Coal Mines AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), is seeking research sites to measure composition of sealed area atmosphere in coal mines. NIOSH seeks to conduct scientific studies of the composition of sealed area atmospheres and the mechanisms of methane accumulation within sealed areas. Research questions to be addressed are: (1) Whether potentially explosive gas mixtures exist within sealed areas, (2) how extensive such mixtures might be, (3) how the gas composition changes over time, (4) whether methane layering exists, (5) the homogeneity of the atmosphere, and (6) how barometric pressure changes impact the sealed atmosphere. NIOSH will document measurements of the composition of the sealed area atmosphere over time, analyze the E:\FR\FM\14APN1.SGM 14APN1

Agencies

[Federal Register Volume 74, Number 70 (Tuesday, April 14, 2009)]
[Notices]
[Page 17202]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-8478]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of a Public Consultation Meeting on Proposed Revisions to 
the NIH Guidelines for Research Involving Recombinant DNA Molecule (NIH 
Guidelines)

    There will be a public consultation meeting to solicit stakeholder 
input regarding the proposed revisions to the NIH Guidelines. The 
meeting will be held on Tuesday, June 23, 2009 at the Hyatt Regency 
Crystal City, 2799 Jefferson Davis Highway, Arlington, Virginia, 22202, 
from approximately 8 a.m. to 5 p.m.
    Discussions will focus on the proposed revisions to the NIH 
Guidelines which include: (1) Broadening the scope of the NIH 
Guidelines, which currently cover laboratory and clinical research 
involving DNA molecules created via recombinant techniques (i.e., 
joining of DNA molecules), to apply to nucleic acids that are 
synthesized chemically or by other means without the use of recombinant 
technology; (2) Revising the criteria for determining when the 
introduction of a drug resistance trait into a microorganism must be 
reviewed by the Recombinant DNA Advisory Committee and approved by the 
NIH Director; and (3) Changing the level of review required for 
recombinant or synthetic experiments involving more than one-half but 
less than two-thirds of the genome of certain viruses in tissue culture 
as described in Section III-E-1 of the NIH Guidelines.
    The Notice of Consideration of a Proposed Action under the NIH 
Guidelines was published in the Federal Register on March 4, 2009 (74 
FR 9411) and may be located at the following link: https://oba.od.nih.gov/rdna/rdna.html.
    For further information concerning this meeting contact Ms. Laurie 
Lewallen, Advisory Committee Coordinator, Office of Biotechnology 
Activities, Office of the Director, National Institutes of Health, 6705 
Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-9838, 
lewallenl@od.nih.gov.
    The meeting will be open to the public, with attendance limited to 
the space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed above in 
advance of the meeting.
    A draft agenda and additional information for the meeting will be 
posted on the OBA Web site: https://oba.od.nih.gov/rdna/rdna.html. 
Background and supplemental information may also be obtained by 
contacting NIH OBA by e-mail oba@od.nih.gov.

    Dated: April 8, 2009.
Jacqueline Corrigan-Curay,
Acting Director, Office of Biotechnology Activities, National 
Institutes of Health.
[FR Doc. E9-8478 Filed 4-13-09; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.